Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-22T20:52:21.724Z Has data issue: false hasContentIssue false

9 - PET and PET/CT in Ovarian Cancer

Published online by Cambridge University Press:  11 September 2009

Norbert Avril
Affiliation:
Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary University of London, London, UK
Rodney Reznek
Affiliation:
St. Bartholomew's Hospital, London
Get access

Summary

Positron Emission Tomography

Positron emission tomography (PET) is a non-invasive imaging technique that measures the distribution of positron emitting radiopharmaceuticals. Depending on the radiolabelled tracer used, PET can determine various physiological and biochemical processes in vivo [1]. PET is highly sensitive, with the capacity to detect nanomolar concentrations of radiotracer and provides superior image resolution to conventional gamma camera imaging. Currently, PET can target several biological features of tumours including glucose metabolism, cell proliferation, perfusion and hypoxia [2]. Most malignant tumours are characterized by elevated glucose consumption, which means that their uptake of the glucose analogue [F-18] fluorodeoxyglucose (FDG) increases. The uptake mechanism and biochemical pathway of the glucose analogue [F-18] fluorodeoxyglucose (FDG) has been extensively studied in vitro and in vivo. The transport of the radiotracer through the cell membrane via glucose transport proteins and subsequent intracellular phosphorylation by the enzyme hexokinase have been identified as key steps for subsequent tissue accumulation (for recent review see [3]). As FDG-6-phosphate is not a suitable substrate for glucose-6-phosphate isomerase, and the enzyme level of glucose-6-phosphatase is generally low in tumours, FDG-6-phosphate accumulates in cells and is visualized by PET.

PET imaging using FDG has been applied for staging of cancer patients for more than a decade now. It is generally accepted that imaging the metabolic activity of tumour tissue provides sensitive and specific information about the extent of disease for many types of tumours [4].

Type
Chapter
Information
Cancer of the Ovary , pp. 156 - 172
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rohren, E. M., Turkington, T. G. and Coleman, R. E.. Clinical applications of PET in oncology. Radiology (2004), 231:305–32.CrossRefGoogle Scholar
Avril, N. E. and Weber, W. A.. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am (2005), 43:189–204.CrossRefGoogle ScholarPubMed
Avril, N.. GLUT1, expression in tissue and F-18 FDG uptake. J Nucl Med (2004), 45:930–2.Google Scholar
Ak, I., Stokkel, M. P. and Pauwels, E. K.. Positron emission tomography with 2-18F fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol (2000), 126:560–74.CrossRefGoogle ScholarPubMed
Weber, W. A., Avril, N. and Schwaiger, M.. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol (1999), 175:356–73.CrossRefGoogle Scholar
Boerner, A. R., Weckesser, M., Herzog, H., et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med (1999), 26:226–30.CrossRefGoogle ScholarPubMed
Short, S., Hoskin, P. and Wong, W.. Ovulation and increased FDG uptake on PET: potential for a false-positive result. Clin Nucl Med (2005), 30:707.CrossRefGoogle ScholarPubMed
Subhas, N., Patel, P. V., Pannu, H. K., et al. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics (2005), 25:1031–43.CrossRefGoogle ScholarPubMed
Kim, S. K., Kang, K. W., Roh, J. W., et al. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging (2005), 32:757–63.CrossRefGoogle ScholarPubMed
Stahl, A., Weber, W. A., Avril, N., et al. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin (2000), 39:241–5.Google ScholarPubMed
Rose, P. G., Adler, L. P., Rodriguez, M., et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol (1999), 17:41–5.CrossRefGoogle ScholarPubMed
Sugawara, Y., Eisbruch, A., Kosuda, S., et al. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med (1999), 40:1125–31.Google ScholarPubMed
Grab, D., Flock, F., Stohr, I., et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol (2000), 77:454–9.CrossRefGoogle ScholarPubMed
Fenchel, S., Grab, D., Nuessle, K., et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology (2002), 223:780–8.CrossRefGoogle ScholarPubMed
Römer, W., Avril, N., Dose, J., et al. Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose. Rofo (1997), 166:62–8.CrossRefGoogle ScholarPubMed
Schroder, W., Zimny, M., Rudlowski, C., et al. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer (1999), 9:117–22.CrossRefGoogle ScholarPubMed
Zimny, M., Schroder, W., Wolters, S., et al. 18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results. Nuklearmedizin (1997), 36:228–33.Google ScholarPubMed
Hubner, K. F., McDonald, T. W., Niethammer, J. G., et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-18F-deoxyglucose (2-18F FDG). Gynecol Oncol (1993), 51:197–204.CrossRefGoogle Scholar
Zimny, M., Siggelkow, W., Schroder, W., et al. 2-Fluorine-18-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol (2001), 83:310–15.CrossRefGoogle Scholar
Torizuka, T., Nobezawa, S., Kanno, T., et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging (2002), 29:797–803.CrossRefGoogle ScholarPubMed
Yen, R. F., Sun, S. S., Shen, Y. Y., et al. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res (2001), 21:3691–4.Google ScholarPubMed
Cho, S. M., Ha, H. K., Byun, J. Y., et al. Usefulness of FDG-PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol (2002), 179:391–5.CrossRefGoogle ScholarPubMed
Chang, W. C., Hung, Y. C., Kao, C. H., et al. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker. Neoplasma (2002), 49:329–33.Google ScholarPubMed
Jimenez-Bonilla, J., Maldonado, A., Morales, S., et al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels. Clin Positron Imaging (2000), 3:231–6.CrossRefGoogle ScholarPubMed
Karlan, B. Y., Hawkins, R., Hoh, C., et al. Whole-body positron emission tomography with 2-18F-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol (1993), 51:175–81.CrossRefGoogle ScholarPubMed
Nakamoto, Y., Saga, T., Ishimori, T., et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol (2001), 176:1449–54.CrossRefGoogle ScholarPubMed
Yuan, C. C., Liu, R. S., Wang, P. H., et al. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report. J Reprod Med (1999), 44:775–8.Google ScholarPubMed
Kubik-Huch, R. A., Dorffler, W., Schulthess, G. K., et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol (2000), 10:761–7.CrossRefGoogle ScholarPubMed
Takekuma, M., Maeda, M., Ozawa, T., et al. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol (2005), 10:177–81.CrossRefGoogle ScholarPubMed
Townsend, D. W., Carney, J. P., Yap, J. T., et al. PET/CT today and tomorrow. J Nucl Med (2004), 45:4S–14S.Google ScholarPubMed
Beyer, T., Townsend, D. W., Brun, T., et al. A combined PET/CT scanner for clinical oncology. J Nucl Med (2000), 41:1369–79.Google ScholarPubMed
Makhija, S., Howden, N., Edwards, R., et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol (2002), 85:53–8.CrossRefGoogle ScholarPubMed
Nanni, C., Rubello, D., Farsad, M., et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol (2005), 31:792–7.CrossRefGoogle ScholarPubMed
Sironi, S., Messa, C., Mangili, G., et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology (2004), 233:433–40.CrossRefGoogle ScholarPubMed
Thrall, M., DeLoia, J. A., McCook, B., et al. Use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol (2005) (submitted).Google Scholar
Bristow, R. E., Carmen, M. G. del, Pannu, H. K., et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol (2003), 90:519–28.CrossRefGoogle ScholarPubMed
Hauth, E. A., Antoch, G., Stattaus, J., et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol (2005), 56:263–8.CrossRefGoogle ScholarPubMed
Bristow, R. E., 2nd, R. L. Giuntoli, Pannu, H. K., et al. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol (2005), 99:294–300.CrossRefGoogle ScholarPubMed
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000), 92:205–16.CrossRefGoogle Scholar
Miller, A. B., Hoogstraten, B., Staquet, M., et al. Reporting results of cancer treatment. Cancer (1981), 47:207–14.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
Tuxen, M. K., Soletormos, G. and Dombernowsky, P.. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer (2001), 84:1301–7.CrossRefGoogle ScholarPubMed
Covens, A. L.. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol (2000), 78:269–74.CrossRefGoogle ScholarPubMed
Maluf, F. C. and Spriggs, D.. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol (2002), 85:18–31.CrossRefGoogle ScholarPubMed
Romer, W., Hanauske, A. R., Ziegler, S., et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood (1998), 91:4464–71.Google ScholarPubMed
Schelling, M., Avril, N., Nährig, J., et al. Positron emission tomography using [F-18] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000), 18:1689–95.CrossRefGoogle Scholar
Brucher, B. L., Weber, W., Bauer, M., et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg (2001), 233:300–9.CrossRefGoogle ScholarPubMed
Weber, W. A., Ott, K., Becker, K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001), 19:3058–65.CrossRefGoogle ScholarPubMed
Weber, W. A., Petersen, V., Schmidt, B., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol (2003), 21:2651–7.CrossRefGoogle ScholarPubMed
H. A. Wieder, B. L. Brucher, F. Zimmermann, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol (2004), 22:900–8.CrossRef
Avril, N., Sassen, S., Schmalfeldt, B., et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol (2005), 23:7445–53.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • PET and PET/CT in Ovarian Cancer
    • By Norbert Avril, Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary University of London, London, UK
  • Edited by Rodney Reznek
  • Book: Cancer of the Ovary
  • Online publication: 11 September 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545887.011
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • PET and PET/CT in Ovarian Cancer
    • By Norbert Avril, Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary University of London, London, UK
  • Edited by Rodney Reznek
  • Book: Cancer of the Ovary
  • Online publication: 11 September 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545887.011
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • PET and PET/CT in Ovarian Cancer
    • By Norbert Avril, Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary University of London, London, UK
  • Edited by Rodney Reznek
  • Book: Cancer of the Ovary
  • Online publication: 11 September 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545887.011
Available formats
×